文献速递糖尿病

β-羟丁酸抑制HDAC3促进claudin-5生成并减轻糖尿病心脏微血管高通透性

β-Hydroxybutyrate inhibits histone deacetylase 3 to promote claudin-5 generation and attenuate cardiac microvascular hyperpermeability in diabetes.
PubMed 文献 · Diabetologia · 2020-10-27

该研究在大鼠链脲佐菌素诱导的糖尿病模型和高糖刺激的人心脏微血管内皮细胞中,评估β-羟丁酸(BHB)对心脏微血管内皮高通透性和claudin-5生成的影响。结果显示BHB治疗10周可促进claudin-5生成并拮抗心脏微血管内皮高通透性,机制涉及BHB抑制HDAC3与Claudin-5启动子结合及与β-catenin的共定位,并特异性增加启动子区H3K14乙酰化。

要点

  • BHB治疗10周促进糖尿病大鼠心脏微血管claudin-5生成并减轻高通透性。
  • BHB(2 mmol/l)抑制高糖诱导的HDAC3与Claudin-5启动子结合。
  • BHB特异性增加Claudin-5启动子H3K14乙酰化,不改变β-catenin核转位或启动子结合。

核心结论

  • BHB通过抑制HDAC3并引起Claudin-5启动子H3K14乙酰化,促进claudin-5生成,拮抗糖尿病相关心脏微血管高通透性。

研究设计与样本

  • 研究在链脲佐菌素诱导的糖尿病大鼠模型和高糖刺激的人心脏微血管内皮细胞(HCMECs)中评估BHB对心脏微血管内皮高通透性和claudin-5生成的影响。

主要发现

  • 10周BHB治疗促进糖尿病大鼠心脏微血管claudin-5生成并拮抗内皮高通透性。
  • BHB促进高糖刺激HCMECs的claudin-5生成并抑制细胞旁通透性。
  • BHB(2 mmol/l)抑制高糖诱导的HDAC3与Claudin-5启动子结合,但β-catenin核转位或启动子结合未因BHB处理而改变。
  • BHB阻止高糖刺激HCMECs中HDAC3与β-catenin的结合和共定位。
  • 质谱鉴定显示BHB处理增加Claudin-5启动子H3K14乙酰化(H3K14ac),且高糖刺激下H3K9乙酰化降低而H3K14ac增加特异性关联BHB处理。

临床怎么用

  • BHB可能通过HDAC3-H3K14ac-claudin-5轴改善糖尿病心脏微血管通透性,为糖尿病心血管并发症提供潜在干预靶点。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS/HYPOTHESIS: Microvascular endothelial hyperpermeability, mainly caused by claudin-5 deficiency, is the initial pathological change that occurs in diabetes-associated cardiovascular disease. The ketone body β-hydroxybutyrate (BHB) exerts unique beneficial effects on the cardiovascular system, but the involvement of BHB in promoting the generation of claudin-5 to attenuate cardiac microvascular hyperpermeability in diabetes is poorly understood. METHODS: The effects of BHB on cardiac microvascular endothelial hyperpermeability and claudin-5 generation were evaluated in rats with streptozotocin-induced diabetes and in high glucose (HG)-stimulated human cardiac microvascular endothelial cells (HCMECs). To explore the underlying mechanisms, we also measured β-catenin nuclear translocation, binding of β-catenin, histone deacetylase (HDAC)1, HDAC3 and p300 to the Claudin-5 (also known as CLDN5) promoter, interaction between HDAC3 and β-catenin, and histone acetylation in the Claudin-5 promoter. RESULTS: We found that 10 weeks of BHB treatment promoted claudin-5 generation and antagonised cardiac microvascular endothelial hyperpermeability in rat models of diabetes. Meanwhile, BHB promoted claudin-5 generation and inhibited paracellular permeability in HG-stimulated HCMECs. Specifically, BHB (2 mmol/l) inhibited HG-induced HDAC3 from binding to the Claudin-5 promoter, although nuclear translocation or promoter binding of β-catenin did not change with BHB treatment. In addition, BHB prevented the binding and co-localisation of HDAC3 to β-catenin in HG-stimulated HCMECs. Furthermore, using mass spectrometry, acetylated H3K14 (H3K14ac) in the Claudin-5 promoter following BHB treatment was identified, regardless of whether cells were stimulated by HG or not. Although reduced levels of acetylated H3K9 in the Claudin-5 promoter were found following HG stimulation, increased H3K14ac was specifically associated with BHB treatment. CONCLUSIONS/INTERPRETATION: BHB inhibited HDAC3 and caused acetylation of H3K14 in the Claudin-5 promoter, thereby promoting claudin-5 generation and antagonising diabetes-associated cardiac microvascular hyperpermeability. Graphical abstract.

来源:Diabetologia,查看原文。版权归原作者所有。

引用

  1. Li B, Yu Y, Liu K, et al. β-Hydroxybutyrate inhibits histone deacetylase 3 to promote claudin-5 generation and attenuate cardiac microvascular hyperpermeability in diabetes. Diabetologia. 2020. PMID: 33106900. doi:10.1007/s00125-020-05305-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。